112 Chapter 3 REFERENCES 1. Bostrom BC, Sensel MR, Sather HN, et al: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 101:3809-17, 2003 2. Kaspers GJL, Veerman AJP, PoppSnijders C, et al: Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology 27:114-121, 1996 3. Veerman AJ, Kamps WA, van den Berg H, et al: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10:957-66, 2009 4. McGrath P, Pitcher L: ‘Enough is enough’: Qualitative findings on the impact of dexamethasone during reinduction/consolidation for paediatric acute lymphoblastic leukaemia. Supportive Care Cancer 10:146-155, 2002 5. de Kloet ER: From receptor balance to rational glucocorticoid therapy. Endocrinology 155:275469, 2014 6. Kellner M, Wiedemann K: Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy. Eur J Pharmacol 583:372-8, 2008 7. Joels M, de Kloet ER: 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The brain mineralocorticoid receptor: a saga in three episodes. J Endocrinol 234:T49-T66, 2017 8. Klok MD, Alt SR, Irurzun Lafitte AJ, et al: Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J Psychiatr Res 45:871-8, 2011 9. ter Heegde F, De Rijk RH, Vinkers CH: The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology 52:92-110, 2015 10. Otte C, Hinkelmann K, Moritz S, et al: Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res 44:339-46, 2010 11. Klok MD, Giltay, E.J., Van der Does, A.J.W., Geleijnse, J.M., Antypa, N., Penninx, B.W.J.H., de Geus, E.J.C., Willemsen, G., Boomsma, D.I., van Leeuwen, N., Zitman, F.G., de Kloet, E.R., DeRijk, R.H.: A common and functional mineralocorticoid receptor haplotype enhances optimism and protects against depression in females. Translational Psychiatry 1, 2011 12. Meijer OC, de Kloet ER: A Refill for the Brain Mineralocorticoid Receptor: The Benefit of Cortisol Add-On to Dexamethasone Therapy. Endocrinology 158:448-454, 2017 13. Grossmann C, Scholz T, Rochel M, et al: Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. European Journal of Endocrinology 151:397406, 2004 14. Warris LT, van den Heuvel-Eibrink MM, Aarsen FK, et al: Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial. J Clin Oncol 34:2287-93, 2016 15. de Ruiter RD, Gordijn MS, Gemke RJBJ, et al: Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and BclI. Haematologica 99:E136-E137, 2014
RkJQdWJsaXNoZXIy MTk4NDMw